Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Phase 2
16
about 1.7 years
60–85
1 site in MA
What this study is about
This trial is testing the safety and tolerability of Foralumab, a medication that targets immune cells in the brain. The goal is to see if this treatment can improve cognition in people with mild cognitive impairment due to early Alzheimer's or dementia by modulating microglial activation.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Foralumab TZLS-401 100 µg
- 2.Take Foralumab TZLS-401 50 µg
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Assessment of microglial function via PET scan using the ligand [18F]PBR06, The number of adverse events in drug versus placebo groups.
Neurology